The Truth About JIA Medications and Cancer Risk 


Here’s what the science says about the link between cancer and the medications used to treat juvenile idiopathic arthritis.

By Timothy Gower

It’s reassuring to know that there are several effective treatments to manage disease activity and relieve symptoms of juvenile idiopathic arthritis (JIA). But for many parents, that comfort is offset by concern, since some reports have linked the most effective medications to an increased risk for cancer. However, while kids with JIA do have modestly increased odds for developing malignant tumors, growing research suggests that medicines used to manage the disease aren’t to blame. The real culprit is more likely uncontrolled inflammation, which not only makes joints ache, but may also increase cancer risk. 

Reports and Reality

Some research has linked the conventional DMARD, methotrexate—a common treatment for JIA, ankylosing spondylitis, lupus, rheumatoid arthritis (RA) and other forms of inflammatory arthritis—to lymphoma, a cancer that arises in immune cells called lymphocytes. The risk appears to be greatest in patients who also have the Epstein-Barr virus [a common virus that causes infectious mononucleosis or “mono”], says Eric Matteson, MD, a rheumatologist at the Mayo Clinic, in Rochester, Minnesota.

Over the last generation, many patients with inflammatory arthritis have benefited from a powerful class of medications called tumor necrosis factor (TNF) inhibitors (i.e., etanercept, adalimumab, infliximab). These drugs, which belong to the biologic class of DMARDs, work by blocking the activity of a key protein that causes inflammation. However, shortly after TNF inhibitors were introduced, the Food and Drug Administration (FDA) began receiving reports that a small number of children and teens treated with the drugs had developed cancer, especially lymphoma. In 2009, the FDA announced that it would require manufacturers of TNF inhibitors to warn doctors about the association between these drugs and cancer. 

But while that may sound alarming, there is far more to the story, explains Timothy Beukelman, MD, an associate professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham School of Medicine. For starters, the FDA lacked reliable data on how many kids in the United States were taking TNF inhibitors. So, it’s hard to know whether the number who developed cancer was unusually high compared to other children who weren’t taking TNF inhibitors, he says.

The FDA also didn’t collect any data on what drugs besides TNF inhibitors had been used by the children who developed cancer, so it’s unknown whether some other medication could have caused malignancies, says Dr. Beukelman. Additionally, many of the cancers reported to the FDA occurred in children who received TNF inhibitors as a treatment for inflammatory bowel disease (IBD). Children with IBD may also be treated with a class of drugs called thiopurines, which are known to cause lymphoma in adults, he says. 

Finally, simply having any form of inflammatory arthritis may increase the risk for lymphoma and other cancers. Lymphomas may be more common in inflammatory arthritis because immune cells are chronically stimulated, which makes them more likely to turn malignant, says Dr. Matteson. It’s no coincidence then, that people with poorly controlled inflammation also have the highest risk for developing lymphoma, he says.

Likewise, another important role of the immune system is to detect and destroy cancer cells. But because people with JIA and other autoimmune diseases have impaired immune systems, they are likely more vulnerable to cancer, says Dr. Beukelman. 

Shedding Light on Safety Concerns

With lingering questions about the safety of TNF inhibitors in mind, Dr. Beukelman and several colleagues decided to study the connection between these drugs, JIA and cancer. Using national databases, they identified nearly 28,000 children with JIA and divided them into two groups: patients who received TNF inhibitors and those who didn’t. By counting cancer cases in each group, they found that the likelihood of developing a malignancy was similar in both. “That means that TNF inhibitors didn’t appear to increase a patient’s background risk of cancer,” says Dr. Beukelman. The research strongly suggests that the benefits of reducing inflammation with medication far outweigh the risks.

Dr. Beukelman’s study determined that kids with JIA are two to three times more likely to develop cancer than children who don’t have inflammatory arthritis. But it’s important to keep that increased risk in perspective: Childhood cancer is very rare to begin with – just one or two kids out of every 10,000 in the United States develop malignancies. In other words, kids with inflammatory arthritis have about a two to six in 10,000 chance of getting cancer. 

However, studies in adult RA patients suggest that methotrexate and TNF inhibitors may modestly increase the risk for skin cancer. If your child is taking either of these drugs, play it safe and make sure they always wear sun block outdoors. 

Diagnosed With Juvenile Arthritis?

Get the latest news and tips about living with Juvenile Arthritis in the Living Your Yes! e-newsletter.

 
I Want to Contribute
I Need Help
  • Donate

    Donate

    Every gift to the Arthritis Foundation will help people with arthritis across the U.S. live their best life.

  • Volunteer

    Volunteer

    Join us and become a Champion of Yes. There are many volunteer opportunities available.

  • Live Yes! INSIGHTS

    Live Yes! INSIGHTS

    Take part to be among those changing lives today and changing the future of arthritis.

  • Partner

    Partner

    Proud Partners of the Arthritis Foundation make an annual commitment to directly support the Foundation’s mission.

Donate


Ways to Give

Every gift to the Arthritis Foundation will help people with arthritis across the U.S. live their best life. Whether it is supporting cutting-edge research, 24/7 access to one-on-one support, resources and tools for daily living, and more, your gift will be life-changing.

Make a Donation

Help millions of people live with less pain and fund groundbreaking research to discover a cure for this devastating disease. Please, make your urgently-needed donation to the Arthritis Foundation now!

Become a Member

Become an Arthritis Foundation member today for just $20. You'll receive a year's worth of Arthritis Today magazine, access to helpful tools, resources, and more.

Make a Honor or Memorial Gift

Honor a loved one with a meaningful donation to the Arthritis Foundation. We'll send a handwritten card to the honoree or their family notifying them of your thoughtful gift.

Gift Planning

I want information on ways to remember the AF in my will, trust or other financial planning vehicles.
 

Volunteer


Volunteer Opportunities

The Arthritis Foundation is focused on finding a cure and championing the fight against arthritis with life-changing information, advocacy, science and community. We can only achieve these goals with your help. Strong, outspoken and engaged volunteers will help us conquer arthritis. By getting involved, you become a leader in our organization and help make a difference in the lives of millions. Join us and become a Champion of Yes.


More About Volunteering

Live Yes! INSIGHTS


Give Just 10 Minutes.

Tell us what matters most to you. Change the future of arthritis.

By taking part in the Live Yes! INSIGHTS assessment, you’ll be among those changing lives today and changing the future of arthritis, for yourself and for 54 million others. And all it takes is just 10 minutes.

Your shared experiences will help:

- Lead to more effective treatments and outcomes
- Develop programs to meet the needs of you and your community
- Shape a powerful agenda that fights for you

Now is the time to make your voice count, for yourself and the entire arthritis community. 

Currently this program is for the adult arthritis community.  Since the needs of the juvenile arthritis (JA) community are unique, we are currently working with experts to develop a customized experience for JA families. 

How are you changing the future?

By sharing your experience, you’re showing decision-makers the realities of living with arthritis, paving the way for change. You’re helping break down barriers to care, inform research and create resources that make a difference in people’s lives, including your own.

Get Started

Partner


Meet Our Partners

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Trailblazer

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Visionary

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Pioneer

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Pacesetter

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Signature

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Supporting

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.